Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma

Background Gastrointestinal (GI) immune-related adverse events (irAEs) commonly limit immune checkpoint inhibitors’ (ICIs) treatment, which is very effective for metastatic melanoma. The independent impact of GI-irAEs on patients’ survival is not well studied. We aimed to assess the impact of GI-irA...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Immunology, Immunotherapy Immunotherapy, 2019-04, Vol.68 (4), p.553-561
Main Authors: Abu-Sbeih, Hamzah, Ali, Faisal S., Qiao, Wei, Lu, Yang, Patel, Sapna, Diab, Adi, Wang, Yinghong
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic Agents, Immunological - adverse effects
Antineoplastic Agents, Immunological - therapeutic use
B7-H1 Antigen - antagonists & inhibitors
Biomarkers
Cancer Research
Colitis
Colitis - etiology
Comorbidity
Diarrhea
Female
Humans
Immune checkpoint inhibitors
Immunologic Factors - adverse effects
Immunologic Factors - therapeutic use
Immunology
Immunosuppression
Kaplan-Meier Estimate
Male
Medicine
Medicine & Public Health
Melanoma
Melanoma - complications
Melanoma - drug therapy
Melanoma - mortality
Melanoma - pathology
Metastases
Metastasis
Middle Aged
Neoplasm Staging
Oncology
Original
Original Article
Patients
Programmed Cell Death 1 Receptor - antagonists & inhibitors
Proportional Hazards Models
Retrospective Studies
Survival
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Gastrointestinal (GI) immune-related adverse events (irAEs) commonly limit immune checkpoint inhibitors’ (ICIs) treatment, which is very effective for metastatic melanoma. The independent impact of GI-irAEs on patients’ survival is not well studied. We aimed to assess the impact of GI-irAEs on survival rates of patients with metastatic melanoma using multivariate model. Methods This is a retrospective study of patients with metastatic melanoma who developed GI-irAEs from 1/2010 through 4/2018. A number of randomized patients who did not have GI-irAEs were included as controls. Kaplan–Meier curves and log-rank test were used to estimate unadjusted survival durations. The Cox proportional hazards model was used to evaluate survival predictors; irAEs were included as time-dependent variables. Results A total of 346 patients were included, 173 patients had GI-irAEs; 124 (72%) received immunosuppression. In multivariate Cox regression, ECOG 2–3 (HR 2.57, 95%CI 1.44–4.57; P  
ISSN:0340-7004
1432-0851
DOI:10.1007/s00262-019-02303-1